US Patent Issued to REGENERON PHARMACEUTICALS on Feb. 18 for "CBLB endonuclease variants, compositions, and methods of use" (Washington Inventors)

ALEXANDRIA, Va., Feb. 19 -- United States Patent no. 12,227,740, issued on Feb. 18, was assigned to REGENERON PHARMACEUTICALS INC. (Tarrytown, N.Y.).

"CBLB endonuclease variants, compositions, and methods of use" was invented by Jordan Jarjour (Seattle), Kyle Havens (Seattle) and Anne-Rachel Krostag (Lake Forest Park, Wash.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency."

The ...